Pena-Shokeir syndrome type 2

Pena-Chokeir syndrome type 2 (PS-2) is a rare genetic disorder belonging to a group of metabolic disorders caused by mutations in the genes responsible for fructose metabolism. This disease is characterized by a deficiency of the enzyme aldatase B, which leads to abnormal accumulation of fructose metabolites in the body. The main clinical manifestations of PS-2 include hypoglycemia, jaundice, vomiting, and liver and kidney dysfunction. The pathology can lead to severe and sometimes life-threatening conditions if diagnosis and treatment are not started in a timely manner. Given the variety of symptoms and their potential severity, PS-2 requires careful clinical monitoring and an interdisciplinary approach to therapy.

History of the disease and interesting historical facts

Pena-Chokeir syndrome was first described in the 1950s when doctors began identifying cases involving abnormalities in carbohydrate metabolism. The main research conducted at that time focused on the effects of excessive fructose consumption on the body. In the 1970s, the genetic nature of the disease became known thanks to discoveries in the field of molecular genetics. Interestingly, symptoms can appear in newborns after the introduction of fructose-containing foods, such as applesauce or fruit juice-based formulas. With the development of genetic research, it became possible to better understand the mechanism of action of the disease and the role of genetic factors in its development.

Epidemiology

Pena-Chokeir syndrome type 2 is estimated to have an incidence of approximately 1 in 20,000–40,000 live births. These figures may vary among populations depending on geographic and ethnic factors. Statistically, most cases of the disease are registered in newborns, but sometimes clinical signs may appear later, in infancy or early childhood. There is evidence of a higher incidence in some population groups, which may be due to genetics and nutritional traditions.

Genetic predisposition to this disease

Pena-Chokeir syndrome type 2 is caused by mutations in the ALDOB gene, which codes for the enzyme aldolase B. More than 30 different mutations in this gene have been identified in research studies, and they can vary in the severity of their effect on fructose metabolism. Transmission of the disease is autosomal recessive, meaning that two alleles of the gene carrying the mutation are required for the disease to manifest. Family histories of Pena-Chokeir syndrome type 2 can identify a predisposition within a population, which can be studied through genetic testing and mutation testing in relatives.

Risk factors for the development of this disease

The most significant risk factors for Pena-Chokeir syndrome type 2 include:

• Hereditary factors: the presence of cases of the disease in the family, which increases the likelihood of the pathology appearing in offspring.
• Genetic counseling: For families with a predisposition, counseling is recommended to determine the risks for future children.
• Environmental factors: exogenous and endogenous factors related to lifestyle and nutrition.
• Poor nutrition in early childhood, especially high fructose diets, may be a trigger for the first manifestations of the disease in susceptible individuals.

Diagnosis of this disease

Diagnosis of Pena-Shokeir syndrome type 2 is made on the basis of a comprehensive clinical examination, which includes:

• Main symptoms: hypoglycemia, vomiting, jaundice, abnormal liver and kidney function, growth failure.
• Laboratory tests: biochemical blood test for fructose and metabolite levels, urine test for fructose content.
• Radiological examinations: ultrasound of the liver and other organs to assess possible structural changes.
• Other types of diagnostics: genetic testing for mutations in the ALDOB gene.
• Differential diagnosis: exclusion of other metabolic disorders and liver diseases.

According to one study, more than 90% cases of the disease can be diagnosed using a comprehensive approach that includes genetic testing.

Treatment

Treatment of Pena-Shokeir syndrome type 2 requires an individual approach and consists of:

• General treatment: elimination of fructose-containing foods from the diet.
• Pharmacological treatment: the possibility of prescribing glucose in acute hypoglycemic conditions and other individually selected drugs.
• Surgery: In rare cases, surgery may be needed to treat complications, such as significant liver damage.
• Other types of treatment: consultation with a nutritionist to create the necessary diet.

According to recent studies, following a strict diet significantly reduces the risk of complications and improves the quality of life of patients.

List of medications used to treat this disease

The main drugs used to treat Pena-Chokeir syndrome type 2 include:

• Glucose (in solution) for emergency treatment of hypoglycemia.
• Glycosides and interrupted carbohydrate components for normalization of metabolic function.
• B vitamins to support metabolism.

Disease monitoring

Patients with Pena-Chokeir syndrome type 2 should be monitored by:

• Regular monitoring of blood glucose levels.
• Assessment of the condition of the liver and kidneys using laboratory and instrumental diagnostic methods.
• Prognosis: if you follow the diet and doctor's recommendations, the disease has a favorable prognosis.
• Complications: Liver failure and other organ dysfunction may occur if the recommended regimen is not followed.

Age-related features of the disease

Pena-Chokeir syndrome type 2 can occur in different age groups:

• In newborns: manifestations may be expressed in the first weeks of life, against the background of the introduction of fructose-containing products into the diet.
• In young children: Symptoms become more noticeable when switching to adult foods containing fructose and sucrose.
• In adults: cases of the disease are less common, but some patients may have an undetected pathology, which requires a thorough examination.

Questions and Answers

• What is Pena-Chokeir syndrome type 2? Pena-Chokeir syndrome type 2 is a rare genetic disorder characterized by a deficiency of aldate B, resulting in impaired fructose metabolism.
• How is Pena-Chokeir syndrome type 2 diagnosed? Diagnosis includes clinical symptoms, laboratory tests for fructose levels, and genetic tests for mutations in the ALDOB gene.
• What is the treatment for Pena-Chokeir syndrome type 2? Treatment includes a fructose-free diet, pharmacological support in case of hypoglycemia and, in rare cases, surgery.
• What is the prognosis for Pena-Chokeir syndrome type 2? The prognosis is favorable if you follow a strict diet and regularly monitor your health.
• At what age can this disease appear? The disease can manifest itself at any age, but is most often diagnosed in newborns and young children after the introduction of fructose-containing products.